ARCHIVES

Immunotherapy Demonstrates Disease Control in Phase II Study

This article is from The Cancer Letter archive.

Vol. 35 No. 9 | September 28, 2012

Download PDF Visit The Full Archive

Related Articles

Cancer Meetings Listed For May and June

April 23, 1993

Tivozanib Does Not Improve OS Compared to Sorafenib

February 22, 2013

In Brief: David Feigal To Head FDA’s Antiviral Division; ODAC To Discuss Melphalan, Amifostine NDAs

January 17, 1992

First NCAB “Road” Hearing In L.A.

September 18, 1987

NI Selects15 Cancer Patient Advocates for Director’s Consumer Liaison Group

November 23, 1997

NCI Program: Hughes Institute Official To Head Cancer Biology

July 23, 1999